- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
People
Dan Donovan specializes in congressional, state attorneys general and parallel government investigations. A former Chief Investigative Counsel in the Senate, Dan co-chairs our Government Advocacy and Congressional Investigations practices perennially recognized by Chambers USA: “King & Spalding is best known for its impressive congressional investigations practice, with several dedicated members working exclusively in this area." Dan has two decades of crisis management experience with government investigations, involving significant legal, public relations and political risks.
Dan represents leading companies, individuals, trade associations, and nonprofit entities and provides effective crisis management counsel. He works at the forefront of controversial and politicized national and state policy issues that frequently lead to investigations and litigation, including congressional, multi-state and federal agency enforcement actions. Particularly experienced in anticipating and responding to congressional committee requests and subpoenas, Dan prepares clients for high-profile hearings and guides them through the unique challenges presented by congressional and parallel government investigations.
Before joining the firm, Dan served as Senior Investigative Counsel to Senator Charles Grassley, current Chairman of Committee on Finance. While serving in the U.S. Senate, Dan managed congressional investigations and oversight hearings. In this role, Dan directed investigations focused on statutory and regulatory compliance, including drug and device safety, drug pricing, and waste, fraud and abuse in Medicare, Medicaid and other government programs. He also handled policy and legislative matters, including the False Claims Act, the Food, Drug, and Cosmetic Act, Medicare and Medicaid programs, and related statutes. Dan also served as Chief Investigative Counsel to the Senate Committee on Small Business, where he managed consumer fraud and small business protection investigations and hearings. He began his congressional career as a Staff Assistant on the Senate Committee on Governmental Affairs, chaired by Senator Fred Thompson, working on the special investigation into the 1996 federal election campaigns.
Dan also provides strategic policy and legislative counsel, and is a frequent speaker on congressional oversight and investigations.
Credentials
J.D., American University
B.A., University of Rochester
District of Columbia
Maryland
News
In the News · Source: Global Legal Chronicle
Cases & Deals
December 31, 2020
King & Spalding Advises on Landmark Medicare Reform Bills BENES Act and PAID Act, Both Passed By Congress
Recognition
June 15, 2020
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2020 Guide
Matters
Providing advice and counsel with respect to congressional oversight activity to the leading pharmaceutical industry trade association and to leading companies in the healthcare, pharmaceutical, medical device, accounting, defense, energy, food, and insurance industries.
Representing a variety of clients in connection with investigations relating to allegations of government fraud, food and product safety and recalls, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and financial conflicts of interest.
Representing multiple pharmaceutical companies in connection with congressional and state attorneys general drug pricing investigations.
See more
Close
Matters
Providing advice and counsel with respect to congressional oversight activity to the leading pharmaceutical industry trade association and to leading companies in the healthcare, pharmaceutical, medical device, accounting, defense, energy, food, and insurance industries.
Representing a variety of clients in connection with investigations relating to allegations of government fraud, food and product safety and recalls, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and financial conflicts of interest.
Representing multiple pharmaceutical companies in connection with congressional and state attorneys general drug pricing investigations.
Representing Pfizer Inc. in connection with congressional investigations.
Representing Toyota in investigations and hearings by the House Energy and Commerce Committee, the House Oversight and Government Reform Committee, and the Senate Commerce, Science and Transportation Committee relating to allegations of unintended acceleration and recalls of certain vehicles with Takata air bag inflators.
Representing a variety of clients on healthcare policy and legislative issues.
Represented a major university and pharmaceutical company in connection with the Select Panel on Infant Lives (authorized under the House Energy and Commerce Committee) investigation relating to fetal tissue research.
Represented a global financial institution in connection with an investigation by the Senate Permanent Subcommittee on Investigations, regarding international tax matters.
Represented a Big Four accounting firm in a Senate Finance Committee investigation of a University’s handling of federal funds.
Represented multiple pharmaceutical companies in House and Senate investigations related to Affordable Care Act enactment and implementation.
Represented medical device companies in connection with House and Senate committee investigations into 510(k) regulatory issues, direct-to-consumer advertising, and payments to physicians.
Represented a leading clean energy technology company in connection with a Senate investigation into Department of Energy grant program.
Represented a major oil company in connection with congressional investigations.
Represented a health insurer in House and Senate investigations related to Affordable Care Act implementation.
Represented a coalition of food product companies in connection with congressional inquiries relating to food safety and regulatory issues.
Represented a medical society in connection with Senate committee investigations in payments to physicians.
Represented individuals in connection with House and Senate committee inquiries and ethics investigations.
Insights
Article
March 11, 2021
Biden Administration - What's Ahead for the Life Sciences Industry?
Client Alert
February 26, 2021
Financial Services Industry Back Under Congress’ Microscope
Energy Law Exchange
February 5, 2021
Georgia Results Flip the Senate and Will Lead to More Congressional Investigations
News
In the News · Source: Global Legal Chronicle
Cases & Deals
December 31, 2020
King & Spalding Advises on Landmark Medicare Reform Bills BENES Act and PAID Act, Both Passed By Congress
Recognition
June 15, 2020
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2020 Guide
Matters
Providing advice and counsel with respect to congressional oversight activity to the leading pharmaceutical industry trade association and to leading companies in the healthcare, pharmaceutical, medical device, accounting, defense, energy, food, and insurance industries.
Representing a variety of clients in connection with investigations relating to allegations of government fraud, food and product safety and recalls, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and financial conflicts of interest.
Representing multiple pharmaceutical companies in connection with congressional and state attorneys general drug pricing investigations.
See more
Close
Matters
Providing advice and counsel with respect to congressional oversight activity to the leading pharmaceutical industry trade association and to leading companies in the healthcare, pharmaceutical, medical device, accounting, defense, energy, food, and insurance industries.
Representing a variety of clients in connection with investigations relating to allegations of government fraud, food and product safety and recalls, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and financial conflicts of interest.
Representing multiple pharmaceutical companies in connection with congressional and state attorneys general drug pricing investigations.
Representing Pfizer Inc. in connection with congressional investigations.
Representing Toyota in investigations and hearings by the House Energy and Commerce Committee, the House Oversight and Government Reform Committee, and the Senate Commerce, Science and Transportation Committee relating to allegations of unintended acceleration and recalls of certain vehicles with Takata air bag inflators.
Representing a variety of clients on healthcare policy and legislative issues.
Represented a major university and pharmaceutical company in connection with the Select Panel on Infant Lives (authorized under the House Energy and Commerce Committee) investigation relating to fetal tissue research.
Represented a global financial institution in connection with an investigation by the Senate Permanent Subcommittee on Investigations, regarding international tax matters.
Represented a Big Four accounting firm in a Senate Finance Committee investigation of a University’s handling of federal funds.
Represented multiple pharmaceutical companies in House and Senate investigations related to Affordable Care Act enactment and implementation.
Represented medical device companies in connection with House and Senate committee investigations into 510(k) regulatory issues, direct-to-consumer advertising, and payments to physicians.
Represented a leading clean energy technology company in connection with a Senate investigation into Department of Energy grant program.
Represented a major oil company in connection with congressional investigations.
Represented a health insurer in House and Senate investigations related to Affordable Care Act implementation.
Represented a coalition of food product companies in connection with congressional inquiries relating to food safety and regulatory issues.
Represented a medical society in connection with Senate committee investigations in payments to physicians.
Represented individuals in connection with House and Senate committee inquiries and ethics investigations.
Insights
Article
March 11, 2021
Biden Administration - What's Ahead for the Life Sciences Industry?
Client Alert
February 26, 2021
Financial Services Industry Back Under Congress’ Microscope
Energy Law Exchange
February 5, 2021
Georgia Results Flip the Senate and Will Lead to More Congressional Investigations
News
In the News · Source: Global Legal Chronicle
Cases & Deals
December 31, 2020
King & Spalding Advises on Landmark Medicare Reform Bills BENES Act and PAID Act, Both Passed By Congress
Recognition
June 15, 2020
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2020 Guide
Credentials
J.D., American University
B.A., University of Rochester
District of Columbia
Maryland